Truvian Sciences

What Truvian Sciences does

Truvian Sciences, Inc. is a San Diego-based diagnostics company founded in 2015 that has developed TruVerus, described as the first FDA-cleared multimodal automated benchtop analyzer integrating clinical chemistry, immunoassay, and hematology in a single instrument. The platform uses proprietary dry reagent technology and AI-powered analysis to deliver lab-accurate multi-assay blood test results from a small whole-blood sample in minutes, targeting point-of-care settings where centralized lab send-outs are typically required. The product is sold as a hardware instrument paired with proprietary assay consumables (recurring per-test revenue) and service and support agreements, and is positioned for primary care clinics, retail pharmacy chains, and direct-to-consumer use cases. Following FDA 510(k) clearance in December 2025 and rapid menu expansion (including CBC) in January 2026, Truvian is transitioning from pre-commercial validation to US commercial deployment, with a stated go-to-market combining direct enterprise sales and channel partnerships (e.g., Shoppers Drug Mart in Canada).

The company has raised more than $206 million in cumulative venture funding across multiple rounds (Series B of $27.1M in 2019, Series C of $105M in 2021, and a $74M round in 2023), with investors including GreatPoint Ventures, Wittington Ventures, TYH Ventures, 7wireVentures, DNS Capital, General Catalyst, Medical Excellence Capital, Tao Capital Partners, and Domain Associates. Leadership includes CEO Jay Srinivasan (since December 2022, replacing founding CEO Jeff Hawkins), Co-Founder and COO Dena Marrinucci, and most recently Chief Medical and Strategy Officer Michael Mina (January 2026). Validation partners include Brigham and Women's Hospital, the Broad Institute of MIT and Harvard, and UC San Diego School of Medicine, and the clinical program has processed more than 50,000 samples from 5,000+ donors. Truvian remains a privately held venture-backed company with no parent organization or public listing.

Name

Truvian Sciences

Legal name

Truvian Sciences, Inc.

Website

https://truvianhealth.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Truvian Sciences is a San Diego-based diagnostics company that developed TruVerus, the first FDA-cleared multimodal benchtop blood testing analyzer integrating chemistry, immunoassay, and hematology for point-of-care use. It sells instruments, recurring consumables, and service contracts to clinics, retail pharmacies, and consumers.

Ownership category

akta.pro rank

Product category

Point-of-Care Diagnostics

NAICS

Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)

akta.pro secondary industry

Hematology POCT (CBC/hemoglobin/hematocrit) (HLAHAOAD)

Keywords

• Benchtop blood analyzer
• Point-of-care diagnostics
• Clinical chemistry immunoassay
• Multimodal hematology testing
• In-vitro diagnostics devices

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

1. TruVerus Analyzer Hardware Sales: Sale of the TruVerus benchtop analyzer instrument to healthcare facilities, clinics, and pharmacy partners. The instrument is the access point that enables the consumables revenue stream.
2. Assay Consumables and Reagent Revenue: Recurring revenue from sale of proprietary assay consumables and dry reagents used with the TruVerus analyzer. Each patient test consumes a set of reagents, generating per-test revenue for Truvian.
3. Service and Support Agreements: Annual service and maintenance contracts for the TruVerus analyzer, providing recurring revenue and ensuring ongoing customer relationships.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Core offering

Truvian Sciences develops and manufactures TruVerus, an FDA-cleared multimodal benchtop blood testing analyzer that combines clinical chemistry, immunoassay, and hematology (CBC with differential) testing into a single integrated device. The platform is intended for use by healthcare providers — including primary care clinics, physician offices, retail pharmacy chains, and broader healthcare facilities — to deliver rapid, lab-equivalent diagnostic results from a single blood draw at the point of care.

Product overview

Truvian Sciences offers TruVerus, a single unified FDA-cleared multimodal benchtop blood testing platform that integrates clinical chemistry, immunoassay, and hematology into one compact instrument. The platform delivers lab-accurate results from a small blood sample in minutes at point-of-care settings. TruVerus serves as the core instrument, with expanding FDA-cleared assay panels delivered as add-on modules including the Tru Kidney Health Test Panel (initial clearance), TruWellness Panel, and individual test modules for cardiovascular health, liver health, core metabolic health, and Complete Blood Count. The company is pursuing additional FDA clearances to expand its comprehensive menu.

Differentiator

Problem solved

Functional benefit

Brands

• TruVerus: FDA-cleared multimodal blood testing benchtop analyzer that combines chemistry, immunoassays, and hematology into a single platform for decentralized care settings.

Products and services

• TruVerus Benchtop Blood Analyzer
• TruWellness Test Panel
• TruVerus CBC with Differential
• Expanded TruVerus Test Menu

Quantifiable outcome

• Over 50,000 blood samples and 5,000+ donors tested through Truvian's clinical validation program, establishing a robust evidence base for regulatory submissions.
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Shoppers Drug MartcoreChannel Partner/ Reseller/ DistributorShoppers Drug Mart, Canada's largest pharmacy chain, partnered with Truvian to lead an onsite evaluation of the TruVerus platform. The partnership aims to deploy Truvian's point-of-care blood testing technology across Shoppers Drug Mart pharmacy locations, enabling convenient blood testing services for Canadian consumers.
• Brigham and Women's HospitalminorStrategic or Co-development PartnerBrigham and Women's Hospital collaborated with Truvian on clinical validation studies for the TruVerus platform, providing clinical expertise and hospital setting context for the technology's performance evaluation.
• Broad Institute of MIT and HarvardminorStrategic or Co-development PartnerThe Broad Institute collaborated with Truvian on clinical research and development, bringing genomic and molecular analysis expertise to support the validation of the TruVerus platform's assay performance.
• UC San Diego School of MedicineminorStrategic or Co-development PartnerUC San Diego School of Medicine partnered with Truvian for clinical validation studies, leveraging academic medical center expertise to evaluate the TruVerus platform's analytical performance and clinical utility.
• Alexandria Real Estate EquitiesminorOthersAlexandria Real Estate Equities is the landlord and infrastructure partner for Truvian's San Diego headquarters at Campus Point Drive, providing the specialized laboratory and office space required for the company's R&D and operational activities.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Abbott Diagnostics: Abbott operates the i-STAT and Piccolo POC blood analyzers, which are the dominant incumbent platforms in point-of-care clinical chemistry and immunoassay testing in clinics and hospitals. Direct overlap with Truvian's core chemistry and immunoassay menu makes Abbott the primary competitive threat in the POC segment.
• Roche Diagnostics: Roche operates the cobas b 101 and cobas h 232 POC systems covering lipid and metabolic panels, plus the broader cobas central lab franchise. Roche competes directly with Truvian in POC lipid and metabolic testing and has unmatched distribution into hospitals and reference labs.
• Siemens Healthineers: Siemens offers the DCA Vantage and epoc Blood Analysis systems for point-of-care HbA1c and blood gas/electrolyte testing. They compete with Truvian in primary care and physician office settings and have deep hospital system relationships.
• HemoCue (Danaher): HemoCue, part of Danaher's diagnostics platform, provides POC hemoglobin and glucose analyzers used in clinics, blood banks, and physician offices. Direct overlap with Truvian's hematology menu, particularly the recently cleared CBC capability.
• QuidelOrtho: QuidelOrtho offers the Triage MeterPro and Sofia platforms for rapid POC immunoassay testing in clinics and urgent care. Competes with Truvian in the POC immunoassay segment and shares similar physician office go-to-market motion.
• Cue Health: Cue Health develops a direct-to-consumer molecular diagnostics platform. Similar to Truvian's DTC ambitions, Cue targets consumer-initiated testing but focuses on molecular assays rather than routine blood chemistry/hematology, making them an adjacent rather than identical peer.

Broad incumbents

• Beckman Coulter (Danaher): Beckman Coulter is a major central laboratory diagnostics provider (hematology and chemistry analyzers) under Danaher. They are not a direct POC competitor but represent the central-lab alternative that Truvian aims to disintermediate for routine testing.
• Bio-Rad Laboratories: Bio-Rad provides clinical diagnostics instruments and quality controls for hospital and reference labs. They represent the broader clinical diagnostics industry that Truvian is targeting with decentralized POC testing.
• Sysmex America: Sysmex is the global leader in hematology analyzers, including POC hematology systems used in clinics and small hospitals. They compete with Truvian's CBC/hematology offering and have established distribution in primary care.

Emerging players

• GenMark Diagnostics (Roche): GenMark (acquired by Roche) developed multiplex molecular POC diagnostics and historically competed with Truvian for clinical development talent (multiple Truvian executives came from GenMark). Their ePlex platform represents an emerging POC molecular competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/truviansciences
• LinkedInlinkedin.com/company/truvian-sciences
• Facebookfacebook.com/truvianhealth

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds4 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Truvian Sciences